NCT02103439: An Open-label Randomized Multicenter Phase III Clinical Study Comparing Safety and Efficacy of Algeron (Cepeginterferon Alfa-2b) and and PegIntron (Peginterferon Alfa-2b) in Combination With Ribavirin as Combined Treatment of Chronic Hepatitis C in Human Immunodeficiency Virus-1 Infected Patients |
|
|
| Completed | 3 | 140 | RoW | Algeron, Cepeginterferon alfa-2b, PegIntron, peginterferon alfa-2b | Biocad | Hepatitis, Hepatitis C, Hepatitis C/ Human Immunodeficiency Virus Coinfection | 08/15 | 08/15 | | |
